Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663158 | 0.78 | SMN1; SMN2 (0.39) | TSHRHPGDSMN1; SMN2MAPT | |
| SCHEMBL6510864 | 0.76 | ALDH1A1 (0.40) | DDAH1TP53TSHRCYP1A2 | |
| SCHEMBL262227 | 0.76 | ALDH1A1 (0.39) | TP53TSHRSMN1; SMN2 | |
| SCHEMBL800638 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL961414 | 0.75 | — | — | |
| SCHEMBL6958166 | 0.75 | ALDH1A1 (0.39) | TSHRHPGD | |
| SCHEMBL7532551 | 0.75 | MAPK1 (0.38) | TP53MAPK1 | |
| SCHEMBL2582333 | 0.73 | LMNA (0.35) | DDAH1TSHRHPGDMAPTALOX12 | |
| SCHEMBL28728927 | 0.73 | DDAH1 (0.34) | DDAH1TSHRHPGDMAPTALOX12 | |
| SCHEMBL28775404 | 0.73 | HSD17B10 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106435-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV HEALTHCARE COMPANY | 2019-04-11 | — | — | US | claimed |
| EP-3260457-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV Healthcare Company (US) | 2017-12-27 | — | — | EP | claimed |
| EP-2549870-B1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV HEALTHCARE CO (US) | 2017-04-19 | — | — | EP | claimed |
| US-20130172551-A1 | Process for Preparing Carbamolypyridone Derivatives and Intermediates | VIIV HEALTHCARE COMPANY | 2013-07-04 | — | — | US | claimed |
| EP-2549870-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV Healthcare Company (US) | 2013-01-30 | — | — | EP | claimed |
| WO-2011119566-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | claimed |
| EP-0912467-B1 | ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE | RHODIA CHIMIE SA (FR) | 2002-04-24 | — | — | EP | claimed |
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | ONCODESIGN PRECISION MEDICINE (FR) | 2026-02-10 | — | — | US | disclosed |
| EP-4146658-B1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PREC MEDICINE OPM (FR) | 2025-10-29 | — | — | EP | disclosed |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PRECISION MEDICINE (FR) | 2023-11-09 | — | — | US | disclosed |
| EP-4146658-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021224320-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2021-11-11 | — | — | WO | disclosed |
| CN-107531614-B | Preparation method of delogevir | 迈兰实验室有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
| EP-0245315-B1 | PROCESS FOR PREPARING $g(a)-HYDROXY CARBONYL COMPOUNDS | L. GIVAUDAN & CIE Société Anonyme (CH) | 1990-04-11 | — | — | EP | disclosed |
| EP-0245315-A1 | PROCESS FOR PREPARING -g(a)-HYDROXY CARBONYL COMPOUNDS. | GIVAUDAN & CIE SA (CH) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | LRRK2, SNCA, ROS1 | DDAH1 1797/4885TP53 2529/4885TSHR 1198/4885 |
| US-20190106435-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | CPS1, CYP3A4, SDHA | DDAH1 2538/4885TP53 1240/4885TSHR 2997/4885 |
| US-20130172551-A1 | Process for Preparing Carbamolypyridone Derivatives and Intermediates | CPS1, CYP3A4, DHPS | DDAH1 1805/4885TP53 689/4885TSHR 2791/4885 |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, RIN1, GRK3 | DDAH1 3096/4885TP53 3932/4885TSHR 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.